The concentration of sGD2 to be added to the binding experiments was selected based on reported median and maximum concentration levels from patients with high-risk neuroblastoma (100 nM and 1000 nM, respectively) also including the level observed in healthy controls (10 nM) [17]. Here, SMARCD2 is linked to neuroblastoma.